Identification of therapeutic drug targets through genetically manipulated mice: are we getting it right?

Klaus I Matthaei1

  • 1Stem Cell & Gene Targeting Laboratory, Structural Biology Program, The John Curtin School of Medical Research, ANU College of Medicine, Biology & Environment, The Australian National University, Canberra, ACT 0200, Australia. Klaus.Matthaei@anu.edu.au

Insights

Genetically modified mice aid disease research, but genetic background matters. Analyzing diverse backgrounds can reveal gene interactions and improve therapeutic development for complex human diseases.

Area of Science:

  • Genetics and Genomics
  • Pharmacology and Therapeutics
  • Disease Modeling

Background:

  • Genetically modified mice are crucial for identifying therapeutic targets in disease control.
  • The genetic background of these mice significantly influences observed phenotypes, potentially leading to data misinterpretation.
  • Uncontrolled genetic backgrounds can obscure the true importance of specific genes in disease states.

Purpose of the Study:

  • To highlight the influence of genetic background in genetically modified mouse models.
  • To explore the potential advantages of analyzing gene function across mixed genetic backgrounds.
  • To improve the understanding of gene function and develop precise molecular therapeutics.

Main Methods:

  • Utilizing genetically modified mice with altered specific gene functions.
  • Comparing phenotypes across different and mixed genetic backgrounds.
  • Analyzing strain-specific modifications in molecular function.

Main Results:

  • Genetic background strongly impacts the phenotype of genetically modified mice.
  • Mixed genetic backgrounds may better approximate the human genome.
  • Potential to identify modifier genes and polymorphisms influencing target gene phenotypes.

Conclusions:

  • Rigorous analysis of strain-specific modifications deepens the understanding of gene function.
  • Mixed genetic backgrounds offer advantages for identifying gene interactions.
  • This approach can lead to more selective and effective molecular therapeutic strategies.

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
In-vitro Mutagenesis01:16

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...